Based on the key measurements obtained from Lixte Biotechnology's financial statements, Lixte Biotechnology Holdings may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter. At this time, Lixte Biotechnology's Net Tangible Assets are comparatively stable compared to the past year. Other Assets is likely to gain to about 111.9 K in 2025, whereas Total Stockholder Equity is likely to drop slightly above 785.9 K in 2025. Key indicators impacting Lixte Biotechnology's financial strength include:
The financial analysis of Lixte Biotechnology is a critical element in measuring its lifeblood. Investors should not minimize Lixte Biotechnology's ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Please note, the imprecision that can be found in Lixte Biotechnology's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Lixte Biotechnology Holdings. Check Lixte Biotechnology's Beneish M Score to see the likelihood of Lixte Biotechnology's management manipulating its earnings.
Lixte Biotechnology Stock Summary
Lixte Biotechnology competes with Allarity Therapeutics, Virax Biolabs, Quoin Pharmaceuticals, Indaptus Therapeutics, and Pasithea Therapeutics. Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company was founded in 2005 and is based in Pasadena, California. Lixte Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 3 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
The reason investors look at the income statement is to determine what Lixte Biotechnology's earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining Lixte Biotechnology's current stock value. Our valuation model uses many indicators to compare Lixte Biotechnology value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Lixte Biotechnology competition to find correlations between indicators driving Lixte Biotechnology's intrinsic value. More Info.
Lixte Biotechnology Holdings is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . At this time, Lixte Biotechnology's Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Lixte Biotechnology by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Lixte Biotechnology Systematic Risk
Lixte Biotechnology's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Lixte Biotechnology volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Lixte Biotechnology correlated with the market. If Beta is less than 0 Lixte Biotechnology generally moves in the opposite direction as compared to the market. If Lixte Biotechnology Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Lixte Biotechnology is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Lixte Biotechnology is generally in the same direction as the market. If Beta > 1 Lixte Biotechnology moves generally in the same direction as, but more than the movement of the benchmark.
Steps to analyze company Financials for Investing
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Lixte Biotechnology is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Lixte has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it. In summary, you can determine if Lixte Biotechnology's financials are consistent with your investment objective using the following steps:
Review Lixte Biotechnology's balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
Study the cash flow inflows and outflows to understand Lixte Biotechnology's liquidity and solvency.
Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
Compare Lixte Biotechnology's financials to those of its peers to see how it stacks up and identify any potential red flags.
Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if Lixte Biotechnology's stock is overvalued or undervalued.
Remember, these are just guidelines and should not be the only basis for investment decisions. It is always important to analyze the leading stock market indicators., conduct additional research and seek professional advice if needed.
Today, most investors in Lixte Biotechnology Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Lixte Biotechnology's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Lixte Biotechnology growth as a starting point in their analysis.
Lixte Biotechnology March 26, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Lixte Biotechnology help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Lixte Biotechnology Holdings. We use our internally-developed statistical techniques to arrive at the intrinsic value of Lixte Biotechnology Holdings based on widely used predictive technical indicators. In general, we focus on analyzing Lixte Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Lixte Biotechnology's daily price indicators and compare them against related drivers.
When running Lixte Biotechnology's price analysis, check to measure Lixte Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lixte Biotechnology is operating at the current time. Most of Lixte Biotechnology's value examination focuses on studying past and present price action to predict the probability of Lixte Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lixte Biotechnology's price. Additionally, you may evaluate how the addition of Lixte Biotechnology to your portfolios can decrease your overall portfolio volatility.